Analyst price targets of where a stock will be in a year’s time are ... well, precisely that. Still, any Morgans clients who moved quickly on the retail broker’s advice to dump Paradigm Biopharmaceuticals must be ruing their timing, given the stock is up a full 20 per cent on where it was since Morgans issued a downgrade last week.
Paradigm Biopharmaceuticals chair Paul Rennie bought the dip.
Loading...
Myriam Robin is a senior writer based in the Melbourne newsroom. She has previously been a Rear Window columnist and editor, and before that reported on financial markets and media. Connect with Myriam on Twitter. Email Myriam at myriam.robin@afr.com
